Composition comprising vlp and amyloid beta peptide

Abstract

The present invention relates to novel uses of a construct consisting of virus-like particle (VLP) structure chemically coupled to a fragment of the A□-1-42 peptide and its pharmaceutically acceptable salts (hereinafter CONSTRUCT), in particular to dosage regimens, modes of and dosage forms for the administration of a CONSTRUCT for the treatment of patients suffering from dementia. in particular dementia of the A

1 . A combination for reducing the severity or delaying onset of dementia in human patients according to the method of  claim 1 , comprising:
 between 5 to 1000 μg of a construct consisting of a virus like particle structure chemically coupled to a fragment of the Aβ-1-42 peptide or its pharmaceutically acceptable salts and,   at least one agent selected from the list of nootropic agent, antidepressants, antipsychotics, antioxydative treatments, vitamin E, lipid-lowering agents, hormone substitution, amyloid lowering agents, aggregation inhibitors, chelators, immunomodulatory agents.   
     
     
         2 . A combination according to  claim 1  wherein:
 (i) the nootropic agent is selected from nootropic plant extracts, calcium antagonists, cholinesterase inhibitors, dihydroergotoxin, nicergoline, piracetame, purine derivatives, pyritinol, vincamine, vinpocentine and memantine; 
 (ii) the antidepressant is selected from SSRIs, SNRIs, NRIs; 
 (iii) the antipsychotic is risperidone; 
 (iv) the antioxydative treatments is selegiline; 
 (v) the lipid-lowering agents is a statins; 
 (vi) the hormone substituent is estrogen; 
 (vii) the amyloid lowering agent is an abeta secretase inhibitors; 
 (viii) the aggregation inhibitor is a beta-sheet blocker; or 
 (ix) the immunomodulatory agent is glatiramer acetate. 
 
     
     
         3 . A commercial package comprising a combination according to  claim 1 , and further comprising instructions for simultaneous, separate or sequential use thereof in the treatment of dementia.